Kelly Shanahan, Director at METAvivor Research And Support, shared a post on X:
“Patients considering clinical trials absolutely want the option crossover (ie, if you’re in the placebo and SOC arm and there is progression you can then get the experimental drug and SOC).”
More posts featuring Kelly Shanahan.